Efficacy of Frankincense and Myrrha in Treatment of Acute Interstitial Cystitis/Painful Bladder Syndrome.
10.1007/s11655-020-3216-2
- Author:
Yung-Hsiang CHEN
1
;
Wen-Chi CHEN
1
;
Kao-Sung TSAI
2
;
Po-Len LIU
3
;
Ming-Yen TSAI
1
;
Tzu-Chun LIN
4
;
Shih-Chieh YU
5
;
Huey-Yi CHEN
6
Author Information
1. Graduate Institute of Integrated Medicine, College of Medicine, Research Center for Chinese Medicine and Acupuncture, Chinese Medicine Research Center, China Medical University, Taichung, Taiwan, China.
2. Department of Applied Cosmetology, Master Program of Cosmetic Science, Hungkuang University, Taichung City, Taiwan, China.
3. Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China.
4. Department of Dermatology, Chung Shan University Hospital, Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan, China.
5. Department of Neurology, Kuang Tien General Hospital, Taichung, Taiwan, China.
6. Graduate Institute of Integrated Medicine, College of Medicine, Research Center for Chinese Medicine and Acupuncture, Chinese Medicine Research Center, China Medical University, Taichung, Taiwan, China. d888208@ms45.hinet.net.
- Publication Type:Journal Article
- Keywords:
acute interstitial cystitis;
cell junction-associated Protein;
frankincense;
myrrha;
painful bladder syndrome
- From:
Chinese journal of integrative medicine
2020;26(7):519-526
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the efficacy of frankincense and myrrha in the treatment of acute interstitial cystitis/painful bladder syndrome (IC/PBS).
METHODS:The effects of frankincense and myrrha on the proliferation and migration of primary human urothelial cells (HUCs) were assessed in vitro. In the animal study, 48 virgin female rats were randomized into 4 groups (12 in each group): (1) control group (saline-injected control); (2) cyclophosphamide (CYP) group (intraperitoneal injected 150 mg/kg CYP); (3) CYP + pentosan polysulfate sodium group (orally received 50 mg/kg pentosan polysulfate sodium); and (4) CYP + frankincense and myrrha group [orally received frankincense (200 mg/kg) and myrrha (200 mg/kg)]. Rats orally received pentosan polysulfate sodium or frankincense and myrrha on day 1, 2, and 3. The experiments were performed on day 4. Pain and cystometry assessment behavior test were performed. Voiding interval values were assessed in rats under anesthesia. Finally, immunohistochemistry and Western blot were used to confirm the location and level, respectively, of cell junction-associated protein zonula occludens-2 (ZO-2) expression.
RESULTS:Low dose frankincense and myrrha increased cell proliferation and migration in HUCs compared with control (P<0.05). Rats with acute IC/PBS rats exhibited lower voiding interval values, pain tolerance, and ZO-2 expression (P<0.05). Voiding interval values and pain tolerance were higher in the frankincense and myrrha group than CYP group (P<0.05). ZO-2 expression in the bladder was increased in the CYP + pentosan polysulfate and frankincense + myrrha groups compared with the CYP-induced acute IC/PBS group (P<0.05).
CONCLUSION:frankincense and myrrha modulate urothelial wound healing, which ameliorates typical features of acute IC/PBS in rats.
